PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics insider sale disclosed: Director Allan Steven Jacobson reported a sale of 1,667 shares of PTC Therapeutics (PTCT) on 08/28/2025 at a price of $50.15 per share, reducing his beneficial ownership to 17,451 shares. The Form 4 was signed by an attorney-in-fact on 09/02/2025. The filing is a routine Section 16 disclosure showing an individual director executed a non-derivative sale.
PTC Therapeutics (PTCT) reported a proposed sale under Rule 144 of 1,667 shares of its common stock, with an aggregate market value of $83,601.72. The shares represent restricted stock that vested and were acquired on 06/17/2025 as compensation.
The filing names Fidelity Brokerage Services LLC as the broker and lists an approximate sale date of 08/28/2025 on the NASDAQ. The company’s total shares outstanding are reported as 79,438,094, making the proposed sale a very small fraction of outstanding stock.
PTC Therapeutics insider transactions on 08/15/2025 show Executive Vice President and CLO Mark Elliott Boulding exercised options to buy 2,813 shares at an exercise price of $25.69 and simultaneously sold 2,813 shares at a weighted average sale price of $48.58 per share under a Rule 10b5-1 plan. After the transactions, Mr. Boulding beneficially owned 103,901 shares of common stock and held 24,899 shares subject to unexercised options. The option was originally granted on February 14, 2024, vests over four years with an initial 25% vesting on February 15, 2025 and subsequent 6.25% quarterly vesting starting May 15, 2025. The Rule 10b5-1 plan was adopted December 5, 2024. The sale prices executed ranged from $48.24 to $49.11 and the filer offers to provide per-trade quantities upon request.
PTC Therapeutics, Inc. reported that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for vatiquinone. This application sought approval of vatiquinone to treat children and adults living with Friedreich’s ataxia, a rare neurodegenerative disease. The company disclosed this development through a press release furnished as an exhibit to this current report.
The Complete Response Letter means the FDA has completed its review of the application but did not approve vatiquinone in its current form, and additional steps would be required before any potential approval. No financial results or updated guidance are discussed in this report.
PTC Therapeutics (PTCT) filed a Form 144 notifying the proposed sale of 2,813 common shares held at Fidelity Brokerage Services, with an aggregate market value of $136,646.45, and an approximate sale date of 08/15/2025 on NASDAQ. The shares were acquired on 08/15/2025 via an option granted 02/15/2024 and payment will be in cash. The filing also lists two prior sales by the same person in May 2025 totaling 2,812 shares for gross proceeds of $129,715.92. The filer affirms no undisclosed material adverse information.
Armistice Capital and Steven Boyd report collective ownership of 4,735,464 shares of PTC Therapeutics common stock, representing 5.96% of the class. The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager and exercises shared voting and dispositive power. Steven Boyd, as managing member of Armistice Capital, is reported with the same shared voting and dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
On 5 Aug 2025, PTC Therapeutics (PTCT) entered a Rights Satisfaction Agreement with holders of roughly 90% of former Censa Pharmaceuticals equity. The deal cancels the royalty-style Net Sales Payments—8% on annual sepiapterin sales ≤ $250 M, 10% on sales > $250 M ≤ $500 M, and 12% on sales > $500 M—originally embedded in the 2020 Censa merger.
In exchange, PTC paid an up-front cash consideration of ≈ $225 M at closing and agreed to up to five additional milestone payments of ≈ $90 M each (aggregate ≈ $450 M) tied to cumulative global sepiapterin net-sales thresholds of $3 B, $5 B, $7 B, $9 B and $11 B achieved within rolling periods of 3–11 consecutive years. Any former Censa holder that later joins the agreement will receive its pro-rata share of the up-front and any future milestones.
The arrangement only affects the specified Net Sales Payments; all other contingent obligations under the original merger agreement remain intact. The agreement contained customary reps, warranties and covenants and closed simultaneously with signing.
PTC Therapeutics, Inc. (PTCT) Form 144 filing: An insider has notified intent to sell up to 10,739 common shares through Fidelity Brokerage around 05 Aug 2025. Based on the stated aggregate market value of $555,662.71, the proposed sale is priced near $51.75 per share. The shares were obtained via restricted-stock vesting on 01 Aug 2025 and will be sold on Nasdaq.
The block represents roughly 0.014 % of PTCT’s 79.26 million shares outstanding, implying negligible dilution or liquidity impact. While the monetary size is modest for a company of PTCT’s scale, the filing indicates near-term insider profit-taking shortly after vesting, a datapoint some investors watch as a sentiment signal.